Editing Transplant rejection (section)

===Gene therapy===
[[Gene therapy]] is another method that can be used. In this method, the genes that cause the body to reject transplants would be deactivated. Research is still being conducted, and no gene therapies are being used to date to treat patients.<ref>{{cite journal | vauthors = Yang JY, Sarwal MM | title = Transplant genetics and genomics | journal = Nature Reviews. Genetics | volume = 18 | issue = 5 | pages = 309–326 | date = May 2017 | pmid = 28286337 | doi = 10.1038/nrg.2017.12 | s2cid = 2222755 }}</ref><ref>{{cite journal | vauthors = Bagley J, Iacomini J | title = Gene therapy progress and prospects: gene therapy in organ transplantation | journal = Gene Therapy | volume = 10 | issue = 8 | pages = 605–611 | date = April 2003 | pmid = 12692588 | doi = 10.1038/sj.gt.3302020 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Giannoukakis N, Thomson A, Robbins P | title = Gene therapy in transplantation | journal = Gene Therapy | volume = 6 | issue = 9 | pages = 1499–1511 | date = September 1999 | pmid = 10490759 | doi = 10.1038/sj.gt.3300981 | doi-access = free }}</ref> Current research tends to focus{{fact|date=January 2022}} on Th1 and Th17 which mediate allograft rejection via the [[Cyclophosphamide#Mechanism of action|CD4]] and CD8 [[T-cell receptor|T cells]].<ref>{{cite journal | vauthors = Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ | display-authors = 6 | title = A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy | journal = The Journal of Experimental Medicine | volume = 205 | issue = 13 | pages = 3133–3144 | date = December 2008 | pmid = 19047438 | pmc = 2605226 | doi = 10.1084/jem.20081937 }}</ref>